Control | AD | |
---|---|---|
Study 1 (paired plasma + CSF) | n = 20 | n = 25 |
Sex, n, female/male (% female) | 12/8 (60) | 14/11 (56) |
Age at LP, yr | 54 (41 to 63) | 76 (71 to 78)b |
CSF Aβ1–42, pg/ml | 1,399 (1189 to 1702) | 709 (588 to 897)b |
CSF Aβ1–42 /Aβ1–40 ratio | 0.094 (0.079 to 0.104) | 0.033 (0.028 to 0.042)b |
CSF t-tau, pg/ml | 185 (136 to 254) | 580 (425 to 655)b |
CSF p-tau, pg/ml | 35 (27 to 45) | 89 (78 to 105 to 126)b |
CSF Ng, pg/ml (MSD) | 291 (251 to 438) | 620 (521 to 818)b |
Plasma Ng, pg/ml (MSD) | 47,451 (21,904 to 90,320) | 36,525 (25,324 to 57,715) |
Plasma, pg/ml (HI-MS) | 21,698 (13,401 to 106,954) | 25,644 (17,262 to 53,900) |
Study 2 (plasma) | n = 17 | n = 13 |
Sex, n, female/male (% female) | 9/17 (53) | 9/13 (69) |
Age at LP, yr | 58 (53 to 68) | 78 (69 to 80)b |
CSF Aβ1–42, pg/ml | 875 (580 to 940) | 330 (268 to 415)b |
CSF t-tau, pg/ml | 300 (210 to 348) | 690 (605 to 980)b |
CSF p-tau, pg/ml | 48 (40 to 61) | 110 (77 to 160)b |